SAN FRANCISCO--(BUSINESS WIRE)--Nov. 17, 2014--
FibroGen, Inc. (NASDAQ:FGEN), a research-based biopharmaceutical company
focused on the discovery, development and commercialization of novel
therapeutics to treat serious unmet medical needs, today announced that
the underwriters of its initial public offering exercised in full their
option to purchase an additional 1,215,000 shares of common stock from
FibroGen at the initial public offering price of $18.00 per share, less
the underwriting discount. With this exercise, the initial public
offering totals 9,315,000 shares of common stock of FibroGen,
representing gross proceeds of approximately $167.7 million, prior to
deducting the underwriting discount and estimated offering expenses.
The Company’s common stock started trading on the NASDAQ Global Select
Market on November 14, 2014. The offering is expected to close on
November 19, 2014, subject to customary closing conditions.
Goldman, Sachs & Co., Citigroup Global Markets Inc., and Leerink
Partners LLC are acting as joint book-running managers of the offering.
RBC Capital Markets, LLC, Stifel, Nicolaus & Company, Incorporated, and
William Blair & Company, L.L.C. are acting as co-managers.
A registration statement relating to these securities was declared
effective by the U.S. Securities and Exchange Commission on November 13,
2014. This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
The offering is being made only by means of a written prospectus. A copy
of the final prospectus relating to these securities, when available,
may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department,
200 West Street, New York, NY 10282, via telephone at (866) 471-2526 or
by email to [email protected];
Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, via telephone at (800) 831-9146
or by email to [email protected];
or Leerink Partners LLC, Attn: Syndicate Department, One Federal Street,
37th Floor, Boston, MA 02110, via telephone at (800) 808-7525, ext. 6142
or by email to [email protected].
About FibroGen
FibroGen is a biotechnology company focused on the discovery,
development, and commercialization of therapeutic agents for treatment
of anemia, fibrosis, cancer, and other serious unmet medical needs.
FibroGen’s FG-3019 fully human monoclonal antibody is in clinical
development for treatment of idiopathic pulmonary fibrosis and other
proliferative diseases, including pancreatic cancer and liver fibrosis.
Roxadustat (FG-4592), FibroGen’s small molecule inhibitor of
hypoxia-inducible factor (HIF) prolyl hydroxylase, is currently in
clinical development for the treatment of anemia in chronic kidney
disease patients who are dialysis-dependent, including hemodialysis and
peritoneal dialysis, and not dialysis-dependent.
Source: FibroGen, Inc.
FibroGen, Inc.
Greg Mann, 415-978-1433
[email protected]
